109 related articles for article (PubMed ID: 29493313)
1. Factors associated with early initiation of disease-modifying drug treatment in newly-diagnosed patients with multiple sclerosis.
Edwards NC; Munsell M; Menzin J; Phillips AL
Curr Med Res Opin; 2018 Aug; 34(8):1389-1395. PubMed ID: 29493313
[TBL] [Abstract][Full Text] [Related]
2. The association of timing of disease-modifying drug initiation and relapse in patients with multiple sclerosis using electronic health records.
Corvino FA; Oliveri D; Phillips AL
Curr Med Res Opin; 2017 Jun; 33(6):1127-1132. PubMed ID: 28318337
[TBL] [Abstract][Full Text] [Related]
3. Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study.
Margolis JM; Fowler R; Johnson BH; Kassed CA; Kahler K
BMC Neurol; 2011 Oct; 11():122. PubMed ID: 21974973
[TBL] [Abstract][Full Text] [Related]
4. Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs.
Birnbaum HG; Ivanova JI; Samuels S; Davis M; Cremieux PY; Phillips AL; Meletiche D
Curr Med Res Opin; 2009 Apr; 25(4):869-77. PubMed ID: 19232041
[TBL] [Abstract][Full Text] [Related]
5. Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment.
Lage MJ; Carroll CA; Fairman KA
J Med Econ; 2013 Sep; 16(9):1146-53. PubMed ID: 23844620
[TBL] [Abstract][Full Text] [Related]
6. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US.
Ivanova JI; Bergman RE; Birnbaum HG; Phillips AL; Stewart M; Meletiche DM
J Med Econ; 2012; 15(3):601-9. PubMed ID: 22376190
[TBL] [Abstract][Full Text] [Related]
7. Understanding the Patient's Journey in the Diagnosis and Treatment of Multiple Sclerosis in Clinical Practice.
Visaria J; Thomas N; Gu T; Singer J; Tan H
Clin Ther; 2018 Jun; 40(6):926-939. PubMed ID: 29803533
[TBL] [Abstract][Full Text] [Related]
8. Relapses and disease-modifying drug treatment in pregnancy and live birth in US women with MS.
Houtchens MK; Edwards NC; Phillips AL
Neurology; 2018 Oct; 91(17):e1570-e1578. PubMed ID: 30266887
[TBL] [Abstract][Full Text] [Related]
9. The effect of age and sex on cost of inpatient facility encounters among patients with multiple sclerosis.
Kozma CM; Meletiche DM; Phillips AL
J Med Econ; 2015; 18(9):704-10. PubMed ID: 25913916
[TBL] [Abstract][Full Text] [Related]
10. Multiple sclerosis disease-modifying drug use by immigrants: a real-world study.
Graf J; Ng HS; Zhu F; Zhao Y; Wijnands JMA; Evans C; Fisk JD; Marrie RA; Tremlett H
Sci Rep; 2023 Dec; 13(1):21235. PubMed ID: 38040796
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Bonafede MM; Johnson BH; Wenten M; Watson C
Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug.
Munsell M; Frean M; Menzin J; Phillips AL
Patient Prefer Adherence; 2017; 11():55-62. PubMed ID: 28115831
[TBL] [Abstract][Full Text] [Related]
13. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs.
Reynolds MW; Stephen R; Seaman C; Rajagopalan K
J Med Econ; 2010 Mar; 13(1):90-8. PubMed ID: 20078189
[TBL] [Abstract][Full Text] [Related]
14. Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population.
Ng HS; Graf J; Zhu F; Kingwell E; Aktas O; Albrecht P; Hartung HP; Meuth SG; Evans C; Fisk JD; Marrie RA; Zhao Y; Tremlett H
Front Immunol; 2021; 12():794075. PubMed ID: 35095869
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
16. Determinants of high cost in multiple sclerosis patients: a claims and chart review study.
Ke X; Navaratnam P; Sasane R; Eisenberg Lawrence DF; Friedman HS; Tulsi BB; Vollmer T
Curr Med Res Opin; 2016 Sep; 32(9):1589-97. PubMed ID: 27207562
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a claims-based measure as an indicator for disease status in patients with multiple sclerosis treated with disease-modifying drugs.
Munsell M; Frean M; Menzin J; Phillips AL
BMC Neurol; 2017 Jun; 17(1):106. PubMed ID: 28583104
[TBL] [Abstract][Full Text] [Related]
18. Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records.
Earla JR; Hutton GJ; Thornton JD; Aparasu RR
Mult Scler Relat Disord; 2020 Oct; 45():102334. PubMed ID: 32629400
[TBL] [Abstract][Full Text] [Related]
19. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Lahoz R; Reynolds T; Korn JR
Curr Med Res Opin; 2014 Aug; 30(8):1461-71. PubMed ID: 24754349
[TBL] [Abstract][Full Text] [Related]
20. Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS.
Horakova D; Rockova P; Jircikova J; Dolezal T; Vachova M; Hradilek P; Valis M; Sucha J; Martinkova A; Ampapa R; Grunermelova M; Stetkarova I; Stourac P; Mares J; Dufek M; Kmetova E; Adamkova J; Hrnciarova T
Mult Scler Relat Disord; 2019 Oct; 35():196-202. PubMed ID: 31400559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
